Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2026 08:15 ET | Source: PharmAla Biotech

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002 to Jupiter Neurosciences in a Transaction Valued at Over $100 Million USD
June 20, 2025 15:57 ET | Source: PharmAla Biotech

PharmAla Files Preliminary Base Shelf Prospectus

Pharmala files short form prospectus
March 20, 2024 10:20 ET | Source: PharmAla Biotech

Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
February 23, 2023 08:00 ET | Source: PharmAla Biotech

Patent Application Published for PharmAla Biotech’s MDMA Analogs

VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6...